3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
92
Neoplasm Metastasis
10
Neoplasms
9
Breast Diseases
4
Advanced Breast Cancer
3
Recurrence
2
Neoplasms by Site
2
Carcinoma, Renal Cell
2
Breast Neoplasms, Male
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Tuberous Sclerosis
1
Thoracic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Diseases
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Post Menopausal Women With Early Breast Cancer
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Multiple Endocrine Neoplasia Type 1
1
Mammary Neoplasms, Animal
1
Lymphoma
1
Lung Neoplasms
1
Lung Diseases
1
Lethal Congenital Contracture Syndrome 2
1
Kidney Neoplasms
1
Invasive Early Breast Cancer
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Interventions
enzalutamide
3
abiraterone
2
ostarine
1
exemestane
1
darolutamide
1
Prednisolone
1
Docetaxel
1
AZD5305
1
AZD3514
1
5'-ACCaagtttcttcAGC-3'
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Bulbo-Spinal Atrophy, X-Linked
×
exemestane
×
Clear all
NCT04869943
2024-01-26
ARTEST
Veru Inc.
Phase 3
Terminated
52 enrolled